1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023


Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Visudyne (verteporfin) is a photosensitizer molecule that was co-developed by QLT PhotoTherapeutics and Novartis Pharma AG for use in a two-step procedure involving the use of a non-thermal laser light, known as PDT. It was initially approved by the FDA in April 2000 for the treatment of patients with predominantly classical subfoveal CNV due to AMD.


- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Visudyne including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Visudyne for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Visudyne performance.
- Obtain sales forecast for Visudyne from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table Of Contents

Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 9
2.1 Related Reports 10
3 Disease Overview 12
3.1 Macular Degeneration Overview 12
3.1.1 Etiology and Pathophysiology 14
3.1.2 Classification 18
3.1.3 Symptoms and Diagnosis 20
3.2 Macular Edema Overview 23
3.2.1 Etiology and Pathophysiology 24
3.2.2 Classification 27
3.2.3 Symptoms and Diagnosis 28
4 Disease Management 31
4.1 Diagnosis and Treatment Overview 31
4.1.1 Macular Edema Diagnosis 31
4.1.2 Macular Degeneration Diagnosis 31
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 32
4.1.4 Clinical Practice 34
5 Competitive Assessment 48
5.1 Overview 48
6 Visudyne (verteporfin) 50
6.1 Overview 50
6.2 Efficacy - Macular Degeneration 52
6.3 Safety 53
6.4 SWOT Analysis 53
6.5 Forecast 54
7 Appendix 55
7.1 Bibliography 55
7.2 Abbreviations 67
7.3 Methodology 70
7.4 Forecasting Methodology 70
7.4.1 Diagnosed ME and AMD Patients 70
7.4.2 Percentage of Drug-Treated Patients 71
7.4.3 General Pricing Assumptions 71
7.4.4 Individual Drug Assumptions 72
7.5 Primary Research - KOLs Interviewed for this Report 73
7.6 Primary Research - High-Prescribers Survey 74
7.7 About the Authors 75
7.7.1 Analyst 75
7.7.2 Therapy Area Director 75
7.7.3 Global Head of Healthcare 76
7.8 About GlobalData 77
7.9 Disclaimer 77

1.1 List of Tables

Table 1: ARM System Classification of AMD 19
Table 2: Symptoms of AMD 20
Table 3: National and International Treatment Guidelines for ME and AMD 33
Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 34
Table 5: Leading Treatments for ME and AMD, 2014 49
Table 6: Product Profile - Visudyne 52
Table 7: Visudyne SWOT Analysis, 2014 53
Table 8: Global Sales Forecast ($m) for Visudyne, 2013-2023 54
Table 9: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 74

1.2 List of Figures

Figure 1: Anatomy of the Eye and Macula 12
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD 21
Figure 3: Color Fundus Photographs of Dry and Wet AMD 21
Figure 4: FAF Imaging of GA 22
Figure 5: Imaging of wAMD 23
Figure 6: CMT in DME 29
Figure 7: RVOs (BRVO and CRVO) on an FA 30
Figure 8: Increased CRT in ME-RVO 30
Figure 9: ME Clinical Treatment Flowchart 40
Figure 10: AMD Clinical Treatment Flowchart 47

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.